PROVECTUS BIOPHARMACEUTICALS INC
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
PVCT$0.04-17.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Deficit
FOR THE THREE MONTHS ENDED MARCH 31, 2024
| Preferred Stock Series D · Preferred Stock Series D-1 · Common Stock · Additional Paid-In · Accumulated Other Comprehensive · Accumulated | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Loss | Deficit | Total | |
| Balance at January 1, 2024 | 12,373,247 | $12,373 | 10,361,097 | $10,361 | 419,522,119 | $419,522 | $244,714,967 | $(60,165) | $(252,690,409) | $(7,593,351) |
| Conversion of 2022 Note to Series D-1 Preferred Stock | - | - | 226,474 | 226 | - | - | 647,935 | - | - | 648,161 |
| Comprehensive loss: | ||||||||||
| Net loss | - | - | - | - | - | - | - | - | (504,042) | (504,042) |
| Other comprehensive loss | - | - | - | - | - | - | - | (415) | - | (415) |
| Balance at March 31, 2024 | 12,373,247 | $12,373 | 10,587,571 | $10,587 | 419,522,119 | $419,522 | $245,362,902 | $(60,580) | $(253,194,451) | $(7,449,647) |
FOR THE THREE MONTHS ENDED MARCH 31, 2023
| Preferred Stock Series D · Preferred Stock Series D-1 · Common Stock · Additional Paid-In · Accumulated Other Comprehensive · Accumulated | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Loss | Deficit | Total | |
| Balance at January 1, 2023 | 12,373,247 | $12,373 | 9,746,626 | $9,747 | 419,497,119 | $419,497 | $242,954,193 | $(35,679) | $(249,588,641) | $(6,228,510) |
| Conversion of 2021 Note to Series D-1 Preferred Stock | - | - | 18,872 | 18 | - | - | 53,992 | - | - | 54,010 |
| Comprehensive loss: | ||||||||||
| Net loss | - | - | - | - | - | - | - | - | (827,454) | (827,454) |
| Other comprehensive income | - | - | - | - | - | - | - | 191 | - | 191 |
| Balance at March 31, 2023 | 12,373,247 | $12,373 | 9,765,498 | $9,765 | 419,497,119 | $419,497 | $243,008,185 | $(35,488) | $(250,416,095) | $(7,001,763) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.